Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06049290 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 1/2
Started2023-10-20
View on ClinicalTrials.gov ↗
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.

Amendment history 2 changes detected by DataLookout

2026-09-12
Primary endpoint(s) modified
WasDose-limiting toxicities（DLT）, Maximum tolerated dose (MTD), Objective Response Rate (ORR)
NowDose-limiting toxicities（DLT）, Maximum tolerated dose (MTD), Objective Response Rate (ORR), Occurrence of adverse event (AE) and serious adverse event (SAE)
2026-09-05
Trial sites reduced: 26 → 21 locations
Trial Details
NCT Number NCT06049290
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Conditions Relapsed/Refractory Multiple Myeloma
Enrollment 342 participants
Start Date 2023-10-20
Primary Completion 2026-10-20 (estimated)
Study Completion 2027-05-20 (estimated)
Updated on ClinicalTrials.gov 2026-09-11